Présentation de l'entreprise
Erasca, Inc. operates as a clinical-stage precision oncology enterprise dedicated to the discovery, development, and commercialization of novel therapies specifically targeting patients afflicted with RAS/MAPK pathway-driven cancers. The company is situated within the healthcare sector, more precisely classified under the biotechnology industry, a domain characterized by high research intensity and significant regulatory hurdles before products reach market. At the time of the latest available data, the entity holds a substantial market capitalization of $5.26 billion and maintains a workforce comprising 103 employees. Despite the impressive valuation implied by the market cap, the absence of reported annual revenue figures indicates that the company is likely in a pre-revenue or early commercialization phase typical of clinical-stage biotechs, where asset value is derived primarily from intellectual property and pipeline potential rather than current sales volume.
Santé financière
The financial statements for Erasca, Inc. report Net Income (TTM) at $-124,546,000 and EBITDA at $-128,298,000, while Revenue (TTM) is listed as N/A. The substantial gap between the reported revenue figure of N/A and the significant negative net income reveals a cost structure dominated by research and development expenses, administrative costs, and potentially commercialization expenditures that are currently outweighing any generated income. Free Cash Flow stands at $-66,761,124, which signifies that the company is burning cash to fund its operations and pipeline advancement, thereby limiting its immediate financial flexibility for non-essential capital expenditures or large-scale acquisitions. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that typically indicates the company has not yet generated revenue sufficient to calculate meaningful margins or is operating at a stage where costs exceed all income. The balance sheet presents a complex picture with Cash totaling $276.08M against Debt of $47.14M, resulting in a Debt to Equity ratio of 14.50, suggesting a highly leveraged structure relative to equity, though the massive cash reserve acts as a significant buffer against this leverage. The Current Ratio is an exceptional 10.04, indicating that the company possesses more than ten times the current assets needed to cover its short-term liabilities, which points to robust short-term liquidity management despite the overall cash burn. Return on Equity is -33.3% and Return on Assets is -18.3%, metrics that collectively reveal that management effectiveness in generating profit from shareholder capital and total assets is currently negative due to the company's stage of development and heavy investment in clinical trials.
Évaluation de la valorisation
The valuation metrics present a distinct divergence between trailing and forward expectations, with a P/E Ratio (TTM) listed as N/A due to negative earnings and a Forward P/E of -31.28. The negative forward P/E implies that analysts or the market are pricing in future earnings that are expected to be negative, reflecting the continued investment required before the company achieves profitability. The Price to Book ratio is 14.81, which indicates that the market is valuing the company at a significant premium of nearly 15 times its book value, a common characteristic for biotechnology firms where the value lies in intangible assets like patents rather than physical book value. Alternative valuation measures such as Price to Sales (N/A) and EV/EBITDA (-39.25) suggest that traditional multiple-based comparisons are not applicable, as the negative EV/EBITDA further underscores the pre-profitability status of the enterprise. The stock has exhibited extreme volatility, trading within a 52-Week High of $18.20 and a 52-Week Low of $1.01, meaning the current price sits significantly below the yearly peak but has recovered from near-ground levels. With a Beta of 1.05, the stock demonstrates price volatility that is slightly higher than the broader market, indicating that it will likely move 5% more aggressively than the S&P 500 during periods of market fluctuation.
Growth & Income
Reported Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which precludes a direct comparison of growth rates but implies that the company is in a phase where historical growth metrics are not yet established or are negligible compared to the scale of investment. As the company does not currently pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, it follows a strategy of reinvesting all available earnings and cash flow back into research, development, and clinical trials to accelerate the pipeline. The absence of a dividend yield confirms that the company prioritizes capital expenditure for growth over returning value to shareholders in the form of cash distributions, a standard practice for clinical-stage biotechnology companies. Consequently, the overall growth and income profile for Erasca, Inc. is defined entirely by its pipeline advancement and the potential for future commercialization, rather than current dividend income or established revenue growth trajectories.